Vivos Therapeutics (VVOS) Analyst Estimates Annual - Discounting Cash Flows
Vivos Therapeutics, Inc.
VVOS (NASDAQ)

* (except for per share items) of USD
Period Ending: 2026
12-31
2025
12-31
2024
12-31
2023
12-31
2022
12-31
2021
12-31
2020
12-31
Number of Analysts 2 1 1 1 1 1 1
Estimated Revenue
Low 19.1 16.5 14.5 13.4 16.3 17.3 12.9
Average 20.9 17.3 15.2 14.0 16.5 17.3 12.9
High 22.7 18.1 15.9 14.6 16.8 17.3 12.9
Estimated EBITDA
Low -20.8 -16.5 -14.5 -13.3 -15.9 -16.3 -12.2
Average -19.1 -15.8 -13.9 -12.8 -15.6 -16.3 -12.2
High -17.4 -15.1 -13.3 -12.2 -15.4 -16.3 -12.2
Estimated EBIT
Low -21.2 -16.8 -14.8 -13.6 -16.3 -16.8 -12.5
Average -19.5 -16.1 -14.2 -13.0 -16.0 -16.8 -12.5
High -17.8 -15.4 -13.5 -12.4 -15.8 -16.8 -12.5
Estimated Net Income
Low -7.67 -8.89 -14.1 -73.6 -33.0 -27.4 -18.3
Average -7.07 -8.40 -13.4 -69.6 -32.3 -27.4 -18.3
High -3.31 -7.92 -12.6 -65.5 -31.6 -27.4 -18.3
Estimated SGA Expenses
Low 32.5 28.2 24.7 22.8 28.8 30.6 22.9
Average 35.6 29.5 25.9 23.8 29.2 30.6 22.9
High 38.7 30.8 27.0 24.9 29.7 30.6 22.9
Estimated EPS
Low -1.160 -1.343 -2.137 -11.12 -27.06 -22.50 -15.00
Average -0.830 -1.270 -2.020 -10.52 -26.50 -22.50 -15.00
High -0.500 -1.197 -1.903 -9.907 -25.94 -22.50 -15.00
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us